Dacomitinib

Dacomitinib
Names
IUPAC name
(2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide
Other names
PF-00299804
Identifiers
1110813-31-4 YesY
3D model (Jmol) Interactive image
ChEBI CHEBI:132268
ChEMBL ChEMBL2105719
ChemSpider 9685914
7422
PubChem 11511120
UNII 2XJX250C20 YesY
Properties
C24H25ClFN5O2
Molar mass 469.95 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Dacomitinib (PF-00299804) is an experimental drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma. It is a selective and irreversible inhibitor of EGFR.[1]

Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals,[2][3][4] Additional Phase III trials are ongoing.[2]

References


This article is issued from Wikipedia - version of the 9/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.